“Immunovia reached several important milestones in the first six months of 2016. Good results were obtained in the American pancreas study that was carried out in collaboration with Knight Cancer Institute. Presentations made at the key global conferences concerning pancreatic cancer were very well received. A specially strong Scientific Advisory Board has been recruited, and involvement from the patient organization has increased. Furthermore, several significant agreements were signed with important cancer centres. The market introduction of IMMray™ PanCan –d, Immunovia’s diagnosis test for early detection of pancreatic cancer, is expected to begin in 2017 and then generate income from the hereditary risk groups in 2018. It is planned to start pancreatic cancer tests for the diabetes group soon afterwards. In addition, it will be possible to use the test for patients seeking help with vague symptoms and where there is a need to swiftly rule out pancreatic cancer. In the second half of 2016 Immunovia’s laboratory in Lund is expected to be completed and subsequently accredited for ISO certification in 2017. CE labelling of IMMray™ PanCan –d will be concluded in 2017. It will then be possible to receive samples from all over Europe to establish early detection of pancreatic cancer, with talks already being held with several prospective customers, i.e. cancer centres and laboratories. In mid-August Immunovia announced its intention to seek a listing on Nasdaq Stockholm’s Main Market in 2017.” Key Indicators +----------------------+-----------------+-----------------+-------------+ |Key Indicators |1 Jan-30 Jun 2016|1 Jan-30 Jun 2015| 2015 | |(SEK 000 unless | | | Full year | |otherwise stated) | | | | +----------------------+-----------------+-----------------+-------------+ |Net sales | 66| 59| 205| +----------------------+-----------------+-----------------+-------------+ |Operating earnings | -5 403| -3 836| -7 424| +----------------------+-----------------+-----------------+-------------+ |Earnings before tax | -5 298| -3 807| -7 384| +----------------------+-----------------+-----------------+-------------+ |Net earnings | -5 298| -3 807| -7 384| +----------------------+-----------------+-----------------+-------------+ |Earnings per share | -0,38| -0,34| -0,65| |before dilution | | | | |(SEK/share) | | | | +----------------------+-----------------+-----------------+-------------+ |Earnings per share | -0,36| -0,33| -0,62| |after dilution | | | | |(SEK/share) | | | | +----------------------+-----------------+-----------------+-------------+ | | | | | +----------------------+-----------------+-----------------+-------------+ | | 30 Jun 2016 | 30 Jun 2015 |31 Dec 2015| +----------------------+-----------------+-----------------+-------------+ |Equity ratio, % | 93| 84| 92| +----------------------+-----------------+-----------------+-------------+ |Gearing ratio, times| 0,07| 0,19| 0,09| +----------------------+-----------------+-----------------+-------------+ Outlook* Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMrayTM, is the result of 15 years of research at CREATE Health – the Center for Translational Cancer Research at Lund University, Sweden. IMMray™ is a technology platform for the development of diagnostic tests and the company’s primary test, IMMray™ PanCan-d, is the first test in the world for early diagnosis of pancreatic cancer. · It is planned to launch IMMray™ PanCan-d on the American and European markets with sales start in 2017 to out-of-pocket customers, with revenues expected to begin in 2018. In coming years Immunovia will address a market that in total is worth around SEK 30 billion. · Immunovia sees great potential in the development of tests for other unsolved problems in cancer and autoimmune diseases via its IMMray™ platform. The next focus area will be tests within SLE. *No changes compared with the Financial Statement dated 24 February 2016. For further information, please contact: Mats Grahn, CEO, Immunovia AB Phone: +46 (0) 70-532 02 30 E-mail: mats.grahn@immunovia.com About Immunovia Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com. ###
Immunovia Half-year report 2016
| Source: Immunovia AB
Attachments
